The makers of Onglyza and Kombiglyze XR are being sued for failing to properly warn consumers about the risks of heart problems or death.
Check your eligibility for compensation below before time runs out.
Victims or the family of victims who have experienced the following may be eligible:
Onglyza and Kombiglyze XR are oral medications used to lower blood sugar levels in patients with Type 2 diabetes. Both drugs are known by the generic name Saxagliptin and are classified as dipeptidyl pepidase-4 (DPP-4) inhibitors. The FDA first approved Onglyza in July 2008 and later approved Kombiglyze XR in November 2010.
In February 2014, the FDA released a drug safety communication regarding Onglyza and Kombiglyze XR side effects. The communication was issued after the New England Journal of Medicine (NEJM) released a study stating that the rate of hospitalization due to heart failure was increased in patients who were on Onglyza and Kombiglyze XR. In April of 2015, the FDA’s Endocirinologic and Metabolic Drugs Advisory Committee recommended adding a label to both drugs in order to warn consumers of the cardiovascular risks.
Attorneys are now accepting claims from individuals who suffered a cardiovascular event such as heart failure, congestive heart failure, cardiac arrest, or death while on either of these Type 2 diabetes medications. If you or a loved one has suffered from the adverse side effects it’s important to act now and file your Onglyza or Kombiglyze claim. You may be entitled to financial compensation.